NDAORALCAPSULE
Approved
Oct 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ACHROMYCIN V (tetracycline hydrochloride) by Pfizer is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. First approved in 1957.
Drug data last refreshed 14h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACHROMYCIN V (tetracycline hydrochloride) is an oral broad-spectrum bacteriostatic antibiotic approved in 1957 that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is active against a wide range of gram-negative and gram-positive bacteria, rickettsiae, chlamydiae, and certain parasites. Tetracycline remains a foundational antibiotic used across multiple indications despite its age.
LOE Approaching
As a legacy product approaching loss of exclusivity with 30% competitive pressure, the brand team is likely focused on managed decline and cost-optimization rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Microbiology Tetracyclines are primarily…
Indications
Worked on ACHROMYCIN V at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.